

DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
CENTERS FOR DISEASE CONTROL

MINUTES OF MEETING

Immunization Practices Advisory Committee
February 7-8, 1984
Atlanta, Georgia

The Immunization Practices Advisory Committee (ACIP) met in Auditorium A at the Centers for Disease Control, Atlanta, Georgia, on February 7-8, 1984. Those in attendance are listed below:

COMMITTEE MEMBERS PRESENT

Dr. James Chin, Chairman
Dr. Ellen S. Alkon
Dr. Anne A. Gershon
Dr. Samuel L. Katz
Dr. Joan K. Leavitt
Dr. Edward A. Mortimer
Dr. Frederick L. Ruben
Dr. William Schaffner II
Dr. Stephen C. Schoenbaum

Liaison Representatives

Dr. Philip A. Brunell (AAP)
Dr. J. Michael Dixon (NACI)
Dr. Theodore C. Eickhoff (AMA)
Dr. Janice Hutchinson (ACP)

Executive Secretary

Dr. Jeffrey P. Koplan

COMMITTEE MEMBERS ABSENT

Dr. D. A. Henderson

Ex Officio Members

Dr. W. S. Jordan, Jr. (NIH)
(represented by Dr. Franklin Tyeryar)
Dr. Harry Meyer, Jr. (FDA)
(represented by Dr. Elaine Esber)

INVITED PARTICIPANTS

Dr. John Barnes
Dr. Cladd E. Stevens
Dr. Arlene McLean
Dr. Eugene D. Shapiro
Dr. David Fedson

HHS STAFF PRESENT

FOOD AND DRUG ADMINISTRATION

Center for Drugs and Biologics

Dr. John Petrucci
Dr. Carolyn Hardigree
Dr. Gerald Quinnan
Dr. Elaine Esber

NATIONAL INSTITUTES OF HEALTH

National Institute of Allergy
and Infectious Diseases

Dr. Franklin Tyeryar
Dr. David L. Klein

CENTERS FOR DISEASE CONTROL

Office of the Director

Dr. James O. Mason
Dr. Gary Noble
Mr. Donald A. Berreth
Mr. Robert M. Alden
Ms. Karen Kaunitz

Center for Infectious Diseases

Dr. Walter R. Dowdle
Dr. Claire Broome
Dr. Alan Kendal
Dr. Mark Kane
Dr. Stephen Cochi
Ms. Julia Garner
Dr. Gary Schatz
Dr. William Winkler
Dr. Gail Bolen

Center for Prevention Services

Dr. Alan Hinman
Dr. Alan Bloch
Dr. Ida Oronato
Dr. Stephen Preblud
Dr. Benjamin Nkowane

The winter meeting of the ACIP was opened by the Chairman, Dr. James Chin, at 8:30 a.m. on February 7, 1984. Dr. Chin introduced Dr. James O. Mason, the new Director of CDC, and Dr. John Barnes, Joint Committee on Vaccination and Immunization, Department of Health and Social Security, London, England.

Dr. Mason welcomed the Committee on behalf of CDC. He stated that both he and the Assistant Secretary for Health appreciate the careful deliberations being made on vaccine statements.

Dr. H. Bruce Dull, former Executive Secretary of the ACIP, gave a review of ACIP for 20 years.

Pertussis

Dr. Alan Hinman, Director of the Division of Immunization, Center for Prevention Services, opened discussion on the proposed supplementary statement on contraindications to receipt of pertussis vaccine. The draft was mailed to the Committee for their review prior to the meeting. In discussion, questions were raised on immunization of children with neurological disorders. Dr. Hinman discussed adverse events associated with receipt of DTP vaccine and the influence of prior personal and family history of convulsions on the incidence of neurologic sequelae of pertussis vaccine.

The supplementary draft statement was revised by a subcommittee and again presented to the Committee on February 8. Suggested changes were made in the draft and the Committee agreed to incorporate the changes and then recirculate it.

Influenza

Dr. Alan Kendal, Chief of the Influenza Branch, Division of Viral Diseases, Center for Infectious Diseases (CID), reviewed recent influenza experience, noting the update in the February 3, 1984, MMWR which showed an increase in the number of outbreaks in influenza-like illnesses in the United States. He lead a discussion of a draft statement on "Prevention and Control of Influenza" which had been mailed to the Committee for their review prior to the meeting. The Committee discussed the determination of high-priority groups and the benefits and risks of influenza vaccination of medical personnel. Dr. Chin asked each member to submit their comments on the draft statement to Dr. Koplan within 2 weeks for further review.

Rabies

Dr. William E. Winkler, Chief of the Viral and Rickettsial Zoonoses Branch, Division of Viral Diseases, CID, summarized data on rabies neutralizing antibody titers in persons who received pre-exposure rabies immunization in the United States. Jean Smith discussed rabies laboratory studies, particularly serologic. Dr. Daniel Fishbein presented a summary of studies of the anamnestic response to intradermally administered human diploid cell rabies vaccine. A rabies draft supplementary statement was handed out. After discussion by the Committee, Dr. Chin asked the Committee to send their comments on the draft to Dr. Koplan within 2 weeks.

Hepatitis B Vaccine (HBV)

Dr. Mark Kane, Division of Viral Diseases, CID, presented a draft statement on Post Exposure Prophylaxis of Hepatitis B for review by the Committee.

Dr. Arlene McLean, Merck, Sharp, & Dohme, discussed available data on persistence of antibody. Dr. Gary Schatz presented data on the status of hepatitis B vaccine and immune globulin safety. The Committee will discuss immune globulin and the screening of pregnant women during the April meeting.

On day two, Dr. Kane continued the discussion of the draft statement. Dr. Cladd Stevens, New York Blood Center, presented data on perinatal transmission. Dr. Chin asked the Committee to send their comments on the draft to Dr. Koplan within 2 weeks.

Rubella

Dr. Hinman initiated the discussion of a draft to update information on the effectiveness, duration of immunity, vaccination in pregnancy, and progress in control of congenital rubella syndrome (CRS). Dr. Chin asked that comments on the draft revision be submitted to Dr. Koplan within 2 weeks.

Immunization Issues in Canada and the United Kingdom

Dr. J. M. S. Dixon, Director of the Provincial Laboratory of Public Health, University of Alberta, Edmonton, Alberta, Canada, outlined some of the matters currently under consideration by the National Advisory Committee on Immunization (NACI) of Canada. A second edition of the "Guide to Immunization for Canadians," now in press, will be distributed to all general practitioners, pediatricians, internists, health departments, and medical schools. The Committee is presently developing a contingency plan for the next pandemic influenza threat. An important factor in the choice between a mass program and a more selective approach is the limited manufacturing facilities for the vaccine in Canada and the expected problem in acquiring vaccine from elsewhere. Statements on use of varicella-zoster immune globulin and influenza vaccination for 1984-85 will be compiled at the NACI meeting to be held February 13-14, 1984.

Dr. John Barnes, Joint Committee on Vaccination and Immunization (JCVI), Department of Health and Social Security, London, England, stated that his Department will soon issue in the Memorandum a revision of routine immunization procedures on "Immunization Against Infectious Disease." Some pediatricians in Britain are calling for relaxing the contraindications to pertussis vaccination. The deliberations of the ACIP on this subject are watched with interest by the JCVI. With the continuing high incidence of pertussis in the United Kingdom, the need for vaccinating a child with neurological disorders is more striking than in the United States. It is the declared intent of the JCVI to improve the uptake of pertussis vaccination (presently 53% in England), measles vaccination (58%), and rubella vaccination of school girls (83%) and adult women. With regard to rubella, the Department together with certain voluntary organizations have launched a long-term campaign to improve vaccination uptake. In addition, a leaflet explaining the childhood immunization procedures to expectant mothers has been included in the Social Security Maternity Benefit Package. Dr Barnes stated that his attendance at this meeting was both interesting and valuable, that the ACIP has common aims with its Canadian and British counterparts, and that there is much to be gained by mutual liaison between these Committees.

Pneumococcal Polysaccharide Vaccine

Dr. Claire Broome and Dr. Gail Bolan, Respiratory and Special Pathogens Branch, Division of Bacterial Diseases, CID, reviewed background information which was sent to the Committee for their review prior to the meeting.

Dr. Eugene D. Shapiro, Department of Pediatrics, Yale School of Medicine, discussed the efficacy of pneumococcal vaccine based on a case-control study he had done.

Dr. David Fedson, Department of Medicine, University of Virginia Medical Center, discussed "Improving the use of Pneumococcal Vaccine Through a Strategy of Hospital-based Immunization."

The Committee discussed the formulation of a statement and the general guidance needed. Dr. Chin assigned a sub-committee consisting of Drs. Schoenbaum and Eickhoff to work with Dr. Broome.

Dr. Broome discussed the potential impact of pneumococcal vaccine on Acute Otitis Media (AOM) and presented slides on the impact on clinical AOM of children.

Adult Immunization Statement

The Committee agreed to withhold publication of the Adult Immunization Statement until after the April meeting when further revisions could be made.

Varicella-Zoster Immune Globulin (VZIG)

It was anticipated that the Varicella-Zoster Immune Globulin (VZIG) statement would be completed and printed before the April meeting.

Other Business

The Committee selected April 5-6, 1984, for the spring meeting. During this meeting, the Committee will discuss and adjust several issues in the adult immunization statement; discuss formulation of statements on pneumococcal, influenza, rabies, and rubella; discuss screening of pregnant women for hepatitis B.

The meeting adjourned at 3 p.m. on February 8, 1984.

I hereby certify that, to the best of my knowledge, the foregoing summary of minutes are accurate and complete.

James Chin 3/27/84
James Chin, M.D. Date